Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection

drug protocol number
TMC435HPC3014
drug sponsor
Janssen-Cilag International NV
drug study
TMC435 (simeprevir)
drug trial site
KFSH & RC-R
drug status
Completed
drug phase